PRINSTON PHARMA INC
PharmaPRINSTON PHARMA INC is a pharmaceutical company focused on Metabolic.
PRINSTON PHARMA INC's Key Drugs
PRINSTON PHARMA INC's core commercial portfolio centers on LINAGLIPTIN AND METFORMIN HYDROCHLORIDE, spanning Metabolic — its most strategically important drugs approved in the last 15 years.
PRINSTON PHARMA INC's Recent FDA Approvals
New NDA/BLA approvals for PRINSTON PHARMA INC over the last two years — novel drugs only, excluding generics and label supplements.
PRINSTON PHARMA INC's Therapeutic Areas
PRINSTON PHARMA INC's approved drugs and pipeline span 1 therapeutic area, led by Metabolic, across 0 biologic and 0 small-molecule drugs. Weighted by commercial stage — approved drugs count most, then late-stage trials.
PRINSTON PHARMA INC's Top Competitors
PRINSTON PHARMA INC's closest competitors by therapeutic-area and drug-target overlap include Merck, Baxter, and Johnson & Johnson. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.
PRINSTON PHARMA INC Pipeline Snapshot
Active clinical trials for PRINSTON PHARMA INC across all therapeutic areas, from ClinicalTrials.gov.
Pro Intelligence Preview
Deep insights for investors and analysts
Revenue Insights
- • LINAGLIPTIN AND METFORMIN HYDROCHLORIDE leads revenue
- • Drug-level revenue analysis
Trial Catalysts
- • Metabolic pipeline focus
- • Phase 3 readout tracking
Patent Risk
- • Patent expiration timeline
- • Revenue at risk analysis
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Revenue forecasts • Trial milestones • Patent risk modeling
Active (1)
Discontinued (0)
Company Info
- First Approval
- -
- Latest
- -
- Applications
- 12